Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

P 276

Next Previous
Search
Drug Profile

P 276

Alternative Names: P-276-00; P276; Riviciclib

Latest Information Update: 11 Jun 2015

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Piramal Life Sciences
  • Developer Piramal Enterprises; Piramal Healthcare
  • Class Antineoplastics; Chromans; Pyrrolidines
  • Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 9 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Head and neck cancer; Malignant melanoma; Mucositis; Multiple myeloma; Pancreatic cancer; Triple negative breast cancer
  • Discontinued Mantle-cell lymphoma; Solid tumours

Most Recent Events

  • 01 Sep 2014 Piramal terminates phase I/II trial in Triple negative Breast cancer (combination therapy, metastatic disease, triple-negative disease) in USA (NCT01333137)
  • 01 Sep 2014 Piramal completes a phase I/II trial in the prevention of Radiation-induced mucositis in patients with locally advanced head and neck cancer receiving chemotherapy in India (NCT01903018)
  • 18 Jul 2013 Piramal completes enrolment in its phase II trial for Triple negative Breast cancer (combination therapy, metastatic disease, triple-negative disease) in USA (NCT01333137)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top